Recruiting

Observational Study

Sponsor:

National Institute on Aging (NIA)

Code:

NCT00094939

Conditions

Alzheimer Disease

Dementia

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The goal of this project is to develop an early diagnostic test for Alzheimer's disease (AD) by monitoring loss of neurons and brain size reductions over a period of five years.

Conditions

Alzheimer Disease

Dementia

Study ID

NCT00094939

Start date

Sep, 2003

Status verified date

Sep, 2009

Completion date

Aug, 2008

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Males and females, from all racial and ethnic categories between the ages of 60-80 years of age, with English as their first language.
  • Residents of the New York City metropolitan area.
  • Minimum of 12 years of education.
  • Participants will be grouped according to the following classifications: normal aging, mild cognitive impairment (MCI), Alzheimer's disease (AD), or frontotemporal dementia (FTD).
  • Participants will agree to ApoE genotyping and DNA banking.

Exclusion Criteria:

  • Past history or MRI evidence of brain damage including significant trauma, stroke, hydrocephalus, lacunar infarcts, seizures, mental retardation or serious neurological disorder.
  • Significant history of alcoholism or drug abuse.
  • History of psychiatric illness (e.g., schizophrenia, mania or depression).
  • Any focal signs or significant neuropathology.
  • A score of 4 or greater on the Modified Hachinski Ischemia Scale suggesting cerebrovascular disease.
  • A total score of 16 or more on the Hamilton Depression Scale to exclude possible cases of primary depression.
  • Evidence of clinically relevant and uncontrolled hypertensive, cardiac, pulmonary, vascular, metabolic or hematologic conditions.
  • Physical impairment of such severity as to adversely affect the validity of psychological testing.
  • Hostility or refusal to cooperate.
  • Any prosthetic devices (e.g., pacemaker or surgical clips) that could be affected by the magnetic field employed during MRI imaging.
  • History of familial early onset dementia.

Study Design

Enrollment

170 participants

Anticipated

Interventions and Outcome Measures

Central Contacts and Locations

Central contacts

Kenneth E. Rich

212-263-7563kenneth.rich@med.nyu.edu

Locations

Center for Brain Health, Silberstein Institute, New York University School of Medicine

Recruiting

New York City, New York, United States, 10016

Contacts

Kenneth E. Rich

212-263-7563kenneth.rich@med.nyu.edu

More Information

Sponsor

National Institute on Aging (NIA)

Last update posted

Dec 14, 2009

Last verified

Sep, 2009

Keywords

  • mild cognitive impairment
  • Alzheimer disease
  • magnetic resonance imaging
  • CSF tau protein
  • Hippocampus

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Institute on Aging (NIA) on 2009-12-14.